Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Vision Medicals Closes $14 Million A Round for Early Pathogen Detection

publication date: Sep 16, 2019

Vision Medicals, a year-old metagenomics company focused on early detection of microbial pathogens, completed a $14 million A funding led by Volcanics Venture and CASH Capital. Based in Guangzhou, Vision's proprietary pathogenic nucleic acid enrichment technology, combined with high-throughput screening and CRISPR, discovers trace amounts of pathogens to identify them more quickly. Using big data, Vision has built two platforms, pathogen metagenomics platform IDseq™ and pathogen rapid diagnosis platform ID-CRISPR™. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital